

UTI HEALTHCARE FUND (Erstwhile UTI Pharma & Healthcare Fund)

An open ended equity scheme investing in the Healthcare Services Sector.

APRIL 2022

Investment Objective

The primary objective of the scheme is to generate long term capital appreciation by investing predominantly in equities and equity related securities of companies/institutions engaged in the Healthcare Services Sector.

However, there can be no assurance or guarantee that the investment objective of the scheme would be achieved.

Date of inception/allotment

28th June, 1999

Fund Manager

Mr. V Srivatsa - B.Com., ACA, CWA, PGDM (IIM-I)
Managing the scheme since Mar-2017

Fund AUM

Fund Size Monthly Average : ₹ 758.99 Crore
Closing AUM : ₹ 776.23 Crore

High/Low NAV in the month

High Growth Option : ₹ 158.4568
Low Growth Option : ₹ 146.0626

Total Expense Ratio

Regular : 2.30
Direct : 1.15

Minimum Investment Amount

Growth: ₹ 5000/-
IDCW:

No. of Unit Holding Accounts

50,718

Load Structure

Entry Load : Nil
Exit Load : < 30 days – 1%; ≥ 30 days – Nil


NAV per unit as on 31st March, 2022

Regular Growth Option : ₹ 157.0027
Regular IDCW Option : ₹ 121.3412
Direct Growth Option : ₹ 171.1902
Direct IDCW Option : ₹ 132.3186

Portfolio as on 31st March, 2022

Equity	% to NAV	Equity	% to NAV
Sun Pharmaceuticals Industries Ltd.	9.96	Narayana Hrudayalaya Ltd	2.06
Cipla Ltd.	9.05	J.B.Chemicals & Pharmaceuticals Ltd	1.88
Dr Reddy's Laboratories Ltd.	7.58	Poly Medicure Ltd.	1.83
Aurobindo Pharma Ltd.	6.38	Torrent Pharmaceuticals Ltd.	1.67
Fortis Healthcare Ltd.	5.69	Metropolis Healthcare Ltd	1.63
Divis Laboratories Ltd.	5.13	AMI Organics Ltd	1.45
Lupin Ltd.	4.77	Gland Pharma Ltd	1.43
Krishna Institute Of Medical Science Ltd	4.47	Proctor & Gamble Health Ltd	1.37
IPCA Laboratories Ltd.	3.85	Alkem Laboratories Ltd	1.34
Apollo Hospitals Enterprise Ltd.	3.25	Pfizer Ltd	1.25
Eris Lifesciences Ltd	3.07	Advanced Enzyme Technologies Ltd	1.23
Ajanta Pharma Ltd	3.07	Sequent Scientific Ltd	1.07
Biocon Ltd.	2.93	FDC Ltd	0.68
Zydus Lifesciences Ltd	2.84	Windlas Biotec Ltd	0.49
Alembic Pharmaceuticals Ltd.	2.69	Net Current Assets	3.27
Suven Pharmaceuticals Ltd	2.62	TOTAL	100.00

Sectoral Breakdown



Active Stock positions

Overweight (Top 5)	%	Underweight (Top 5)	%
Krishna Institute Of Medical Science Ltd	4.2	Sun Pharmaceuticals Industries Ltd.	-5.7
Aurobindo Pharma Ltd.	3.4	Apollo Hospitals Enterprise Ltd.	-4.0
Fortis Healthcare Ltd.	3.3	Divis Laboratories Ltd.	-3.8
Eris Lifesciences Ltd	2.8	Laurus Labs Ltd.	-3.7
Ajanta Pharma Ltd.	2.3	Max Healthcare Institute Ltd	-2.0

Market Capitalisation (%)

	Large	Mid	Small
Fund	42	30	28
Benchmark	54	30	16

Quantitative Indicators

	Fund	Benchmark
Beta	0.89	1
Standard Deviation (Annual)	18.46%	20.12%
Sharpe Ratio	0.99%	
Portfolio Turnover Ratio (Annual)	0.44	
P/B	5.94	7.10
P/E	39.54	45.13
ROE	14.99	15.60

As on 31st March, 2022

Portfolio Details

% of Top 10 Stocks	60.14
Median Market Cap (₹ Cr)	39,236
Weighted Average Market Cap	58,928
Number of Securities	30

All figures given are provisional and unaudited.

Fund Performance Vs Benchmark (CAGR) as on 31st March, 2022 Growth of ₹ 10000

Period	NAV Growth (%)	S&P BSE Healthcare (%)	Nifty 50 (%)	NAV Growth (₹)	S&P BSE Healthcare (₹)	Nifty 50 (₹)
1 Year	12.65	14.59	20.26	11,265	11,459	12,026
3 Years	22.14	19.88	15.86	18,231	17,237	15,559
5 Years	11.87	10.41	15.14	17,527	16,412	20,244
Since inception*	14.25	14.50	NA	2,07,748	2,18,350	NA

Different plans have a different expense structure. The performance details provided herein are of regular plan.
*Compounded annualized Growth Rate.

For performance details of other Schemes managed by the Fund Manager, please refer the respective Scheme sheets as listed in page 65 in 'Fund Manager Summary'. N.A Not Available. Schemes Managed by Mr. V Srivatsa. As TRI data is not available since inception of the scheme, benchmark performance is calculated using composite CAGR of Nifty Pharma. PRI values from 28th June 1999 to 3rd April 2006. TRI Value From 4th April 2006. The performance of the benchmark is calculated using total return index variant of the benchmark index.

SIP Returns as on 31st March, 2022

Period	Investment Amount (₹)	Fund Value (₹)	S&P BSE Healthcare (₹)	Nifty 50 (₹)	Yield (%) Fund	Yield (%) S&P BSE Healthcare	Yield (%) Nifty 50
1 Year	1,20,000	1,17,381	1,17,905	1,28,178	-4.04	-3.24	12.95
3 Years	3,60,000	5,07,464	5,05,734	5,02,998	23.66	23.41	23.02
5 Years	6,00,000	9,48,143	9,28,150	9,26,133	18.37	17.50	17.41
7 Years	8,40,000	13,54,358	13,01,371	14,75,759	13.42	12.30	15.82
10 Years	12,00,000	23,87,203	22,89,335	25,87,688	13.19	12.41	14.70
15 Years	18,00,000	59,05,954	59,27,907	52,28,474	14.51	14.55	13.10
Since inception	20,80,000	81,98,338	83,66,524	74,21,333	14.23	14.43	13.26

Note: Systematic Investment Plan (SIP) returns are worked out assuming investment of ₹ 10,000/- every month at NAV per unit of the scheme as on the first working day for the respective time periods. The loads have not been taken into account. *Since inception for above mentioned schemes is taken for the period December 2004 to March 2022 (Since SIP facility was introduced in November 2004. Past performance may or may not be sustained in future.

For Product Label, Refer Page no. 66-69.

For performance details of other Schemes managed by the Fund Manager Summary

Sr. No	Name of the Fund Manager and Overall Experiences in number of year	Funds Managed	Performance data refer page no.
1	Mr. Vetri Subramaniam, 27	UTI Multi Asset Fund UTI Focused Equity Fund	32 17
2	Mrs. Swati Kulkarni, 34	UTI Mastershare Unit Scheme UTI MNC Fund UTI Dividend Yield Fund UTI-Master Equity Plan Unit Scheme	11 17 18
3	Mr. Ajay Tyagi, 18	UTI Unit Linked Insurance Plan (Equity Portion) UTI Flexi Cap Fund (Earlier Known as UTI EQUITY FUND)	35 13
4	Mr. V Srivatsa, 19	UTI Core Equity Fund UTI Healthcare Fund UTI Hybrid Equity Fund (Along with Mr. Sunil Madhukar Patil) UTI Equity Savings Fund (Equity Portfolio) UTI Retirement Benefit Pension Fund (Equity Portion) UTI Capital Protection Oriented Schemes (Equity Portion); UTI Dual Advantage Fixed Term Funds (Equity Portion);	12 23 31 36 38
5	Mr Sachin Trivedi, 20	UTI Transportation & Logistic Fund UTI Infrastructure Fund	24 21
6	Mr. Amit Premchandani, 15	UTI Banking and Financial Services Fund UTI Value Opportunities Fund UTI Regular Savings Fund (Equity Portion)	22 14 34
7	Mr. Vishal Chopda, 12	UTI India Consumer Fund UTI Children's Career Fund-Savings Plan (Equity Portion) UTI Children's Career Fund - Investment Plan UTI Long Term Equity Fund (tax Saving)	20 37 39 25
8	Mr. Amandeep Chopra, 28	UTI Regular Savings Fund (Debt Portion) UTI Bond Fund UTI Liquid Cash Plan (along with Mr. Amit Sharma)	34 53 42
9	Mr. Sudhir Agrawal, 21	UTI Short Term Income Fund UTI Floater Fund UTI Dynamic Bond Fund UTI Gilt Fund	47 46 52 54
10	Mr. Ritesh Nambiar, 13	UTI Credit Risk Fund UTI Ultra Short Term Fund UTI Medium Term Fund	50 44 51
11	Mr. Sunil Madhukar Patil, 31	UTI Fixed Maturity Plan, UTI Fixed Term Income Funds, UTI Fixed Income Interval Fund & UTI Fixed Income Interval Fund Series II, UTI Capital Protection Oriented Schemes (Debt Portion), UTI Dual Advantage Fixed Term Funds (Debt Portion), UTI Equity Savings Fund (Debt Portion), UTI Hybrid Equity Fund (Debt Portion), UTI Multi Asset Fund (Debt Portion) UTI Children's Career Fund - Savings Plan (Debt Portion) UTI Retirement Benefit Pension Fund (Debt Portion) UTI Unit Linked Insurance Plan (Debt Portion)	36 31 32 37 38 35
12	Mr. Amit Sharma, 10	UTI Money Market Fund (along with Mr. Anurag Mittal) UTI Arbitrage Fund (along with Mr Sharwan Kumar Goyal) UTI Liquid Cash Plan (along with Mr.Amandeep Chopra) UTI Overnight Fund	43 33 42 41
13	Mr Sharwan Kumar Goyal, 12	UTI Arbitrage Fund (along with Mr. Amit Sharma) UTI Gold Exchange Traded Fund UTI-Nifty Exchange Traded Fund (UTI-Nifty ETF) UTI-Sensex Exchange Traded Fund (UTI-Sensex ETF) UTI Nifty Next 50 ETF UTI S&P BSE Sensex Next 50 ETF UTI Nifty Index Fund UTI Nifty Next 50 Index Fund UTI Bank ETF UTI Nifty200 Momentum 30 Index Fund UTI Multi Asset Fund (Equity/Gold Portion) UTI Sensex Index Fund UTI Nifty Midcap 150 Quality 50 Index Fund UTI S&P BSE Low Volatility Index Fund	33 26 27 28 32 29
14	Mr Ankit Agarwal	UTI Mid Cap Fund (Equity/Gold Portion) UTI SmallCap Fund	15 16
15	Mr. Anurag Mittal	UTI Money Market Fund (Along with Mr. Amit Sharma) UTI Treasury Advantage Fund UTI Banking & PSU Debt Fund UTI Corporate Bond Fund	43 45 48 49